Report Overview
The market for electroretinography reached US$ 48.42 million in 2022, and it is anticipated to rise rapidly to US$ 93.52 million by 2030. Throughout the anticipated period (2023-2030), the market is expanding at a CAGR of 7.2%.
Electroretinography is the electrical analysis of the retina, the layer of the eye that detects light. Electroretinography provides a wealth of objective, crucial knowledge about retinal function and health. ERG is essential in the diagnosis of hereditary and acquired eye diseases and feeds research into the factors that influence the health of the retina or the visual pathways.
For More Insights request free Sample: https://www.datamintelligence.com/download-sample/electroretinography-market
Market Dynamics
Increasing incidence of retinal disorders
Retinal issues are a growing contributor to vision impairment in the developing countries. Globally, ocular morbidity and visual impairment are significantly influenced by retinal illnesses. Age-related macular degeneration (AMD) is the most common cause of permanent blindness in the elderly, while diabetic retinopathy (DR) is the most common cause of blindness in persons in their working years in industrialised countries. Retinal diseases are a leading cause of blindness in the poor countries. Longer life expectancies and different lifestyles are significant contributing factors, as well as systemic diseases like diabetes mellitus and hypertension.
For instance, the Centres for Disease Control and Prevention (CDC) provides prevalence data for the most common eye problems and diseases. In the US, refractive errors are the most prevalent eye conditions. One of the main causes of blindness in adults is age-related macular degeneration. Macular degeneration may become more likely if large drusen deposits continue to form. Nearly a million of the over 12 million persons in the United States who are 40 years of age or older who have vision impairment are blind. The World Health Organisation statistics, which support similar findings, estimate that 2.2 billion people worldwide suffer from eye and vision problems. because the market is being driven by an increase in retinal diseases.
The market is hurt because wealthy patients typically cannot get diagnostic tests. Utilising hospital data, national labour statistics, and government insurance reimbursement, the cost projections were created. Over a three-year period, testing was expected to cost a total of $114 962, or $1716 per patient. The market will also be hampered by the expense of the testing and processes.
View Full Report: https://www.datamintelligence.com/research-report/electroretinography-market
Electroretinography Market Companies
Key players are Electro-Diagnostic Imaging, Inc., Roland Consult Stasche & Finger GmbH, Diagnosys LLC, Konan Medical USA, Inc., CSO Italia, LKC Technologies, Inc, Welch Allyn, Diopsys, Inc., Metrovision, Costruzione Strumenti Oftalmici.
Related Reports:
Sign in to leave a comment.